OmniAb Operations, Inc.

Material Contracts Filter

EX-10.19
from 10-12G/A 74 pages Office/Laboratory Lease Between Emery Station Office II, LLC (Landlord) and Ligand Pharmaceuticals Incorporated (Tenant) 5980 Horton Street Emeryville, California
12/34/56
EX-10.22
from 10-12G 52 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amended and Restated License Agreement This Amended and Restated License Agreement (“Agreement”) Is Made on May 29, 2020 by and Between
12/34/56
EX-10.21
from 10-12G 51 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Research, Development and Commercialization Agreement by and Between Icagen, Inc. and Cystic Fibrosis Foundation Research, Development and Commercialization Agreement Contents
12/34/56
EX-10.20
from 10-12G 21 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Antibody License Agreement
12/34/56
EX-10.19
from 10-12G 85 pages Lab Lease Between Emery Station Office II, LLC (Landlord) and Crystal Bioscience, Inc. (Tenant) Emery Station North Emeryville, California
12/34/56
EX-10.18
from 10-12G 16 pages OmniAb, Inc. Indemnification Agreement
12/34/56
EX-10.17
from 10-12G 27 pages OmniAb, Inc. Severance Plan and Summary Plan Description Effective Date: [ ], 2022
12/34/56
EX-10.16
from 10-12G 14 pages Change in Control Severance Agreement
12/34/56
EX-10.15
from 10-12G 4 pages OmniAb, Inc. Director Compensation and Stock Ownership Policy I. Director Compensation
12/34/56
EX-10.14
from 10-12G 20 pages OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan
12/34/56
EX-10.13
from 10-12G 20 pages OmniAb, Inc. 2022 Omniab Service Provider Assumed Award Plan
12/34/56
EX-10.20
from 10-12G 53 pages Amended and Restated License Agreement This Amended and Restated License Agreement (“Agreement”) Is Made on May 29, 2020 by and Between
12/34/56
EX-10.19
from 10-12G 51 pages Research, Development and Commercialization Agreement by and Between Icagen, Inc. and Cystic Fibrosis Foundation Research, Development and Commercialization Agreement Contents
12/34/56
EX-10.18
from 10-12G 21 pages Antibody License Agreement
12/34/56
EX-10.17
from 10-12G 85 pages Lab Lease Between Emery Station Office II, LLC (Landlord) and Crystal Bioscience, Inc. (Tenant) Emery Station North Emeryville, California
12/34/56
EX-10.16
from 10-12G 16 pages OmniAb, Inc. Indemnification Agreement
12/34/56
EX-10.12
from DRS/A 85 pages Lab Lease Between Emery Station Office II, LLC (Landlord) and Crystal Bioscience, Inc. (Tenant) Emery Station North Emeryville, California
12/34/56